Sixty-nine consecutive patients (median age 54 years) were prospectively enrolled in a single-institution protocol for allogeneic transplantation with adjusted non-myeloablative fludarabine-melfalan-based conditioning including cyclosporin A and MMF, and one of three modes of serotherapy. Thirty-one donors (45%) were unrelated. The first cohort of 29 had ATG (Thymoglobulin 2 mg/kg Â 3 days), the subsequent 26 had Campath 30 mg Â 3 days subcutaneously, and the final cohort of 14 had 30 mg Campath once. The groups were similar as regards age, diagnosis and risk factors. Campath-patients had no acute toxicity, fewer days with fever and antibiotics, and required fewer transfusions than ATG-treated patients. 3-d-Campath patients showed lower lymphocyte counts from day þ 4, and CD4 þ , CD8 þ , CD19 þ and NK cells recovered slower than in ATG-treated patients. More Campath patients developed mixed chimerism that required DLI. 3-d-Campath induced more serious and opportunistic infections than ATG, which resulted in a greater non-relapse mortality and an impaired overall survival despite a low tumor-related mortality. The change of the Campath dosing schedule to one dose abrogated the deleterious effect of 3-d-Campath on immune recovery, severe infections and survival. Subcutaneous Campath is simple and provides strong immune suppression with no early toxicity, but dose limitation to 30 mg once is recommended.
Introduction
Allogeneic stem cell transplantation provides a possibility for long-term immune control of malignancy, 1 following the establishment of a full donor chimerism. Immune suppression, but not myeloablation is required for engraftment. 2 The experience with allogeneic transplantation following minimal conditioning 3 has paved the road for adjusted conditioning using immunosuppression combined with antitumor therapy [4] [5] [6] that is less toxic but provides similar tumor control as myeloablative conditioning. 7 Most non-myeloablative conditioning protocols include serotherapy for enhanced immune suppression to reduce the risk for rejection, and to provide an in vivo T-cell modulation of the graft aiming at less graft-versus-host disease. 8, 9 Most patients experience significant acute side effects from antithymocyte globulin (ATG). 10 Non-myeloablative conditioning including Campath-1H (alemtuzumab) provides a low risk for GvH with promising overall survival, 11 despite an increased risk for CMV disease. 12 Campath depletes both B-and T-cells, 13 and might thus also reduce the risk for EBV-induced post transplantation lymphoproliferative disease.
14 It might well also enhance the antitumor effect of chemotherapy in the conditioning against lymphoid malignancies. 15, 16 Campath is registered for intravenous infusion, which leads to frequent acute febrile reactions. However, subcutaneous injections of Campath have been utilized for autoimmune disease 17 and for chronic lymphocytic leukemia. 18 Our aims for the conditioning for allogeneic transplantation include reduction of the acute toxicity with preserved short-term tumor control, safe engraftment, and early establishment of full donor chimerism. Within our protocol using adjusted non-myeloablative conditioning, we therefore prospectively replaced ATG with Campath given subcutaneously for 3 days. When compared to ATG, the short-term toxicity profile from Campath was very beneficial, and the requirements for transfusions and antibiotics were also reduced. However, patients conditioned with Campath had a slower recovery of lymphoid cells, more mixed chimerism, more severe infections, and an impaired overall survival. To overcome these deleterious effects, the Campath dose schedule was changed to one injection on day À5, which resulted in a similar immune recovery as with ATG, with less acute side reactions.
Patients and methods

Patients
Sixty-nine patients with a median age of 54 years (range 9-66) from the southeast part of Sweden, with 1 million inhabitants, were prospectively enrolled during 1999-2003 (Table 1) in a single-center protocol using adjusted nonmyeloablative conditioning. 7 No patient had previous exposure to Campath. In short, conditioning for alloSCT for patients with acute leukemia and aggressive lymphomas consisted of fludarabine 50 mg total dose i.v. daily and cytosine arabinoside 1 g/m 2 i.v. per 2 h daily, days À5 to À1, and melphalan 80 mg/m 2 on day À1. Patients with myeloma, other lymphoproliferative and other diseases received cyclophosphamide 300 mg i.v. or orally daily, days À5 to À1, instead of ara-C. Most patients had mobilized blood stem cells (Table 1) , and 45% of the donors were unrelated. Oral cyclosporin A (target serum level 150-200 nmol/l, tapering from day 42), and mycophenolate mofetil (MMF) (15 mg/kg twice daily on days 1-28) was used for GvH prophylaxis to avoid mucositis and delayed engraftment. Serotherapy consisted initially of rabbit ATG (Thymoglobulin Sangstat, 2 mg/kg i.v. per 2 h daily, days À4 to À2; total dose 6 mg/kg). From August 2001 until May 2002, 26 patients received Campath, provided by Millenium-ILEX (UK), 10 mg/ml, 30 mg daily, days À3 to À1 (1 ml per site in three abdominal sites) by subcutaneous injections (total dose 90 mg), following oral pretreatment with betamethasone 4 mg, clemastin 2 mg, and paracetamol 1 g. 19 The protocol was approved by the Swedish Medical Products Agency and the local ethics committee. Owing to the observed delay of immune recovery with increased risk of fatal infections, the Campath schedule was changed to 30 mg subcutaneously on day À5 for 14 subsequent patients.
Patients routinely received oral fluconazole and acyclovir, and cotrimoxazole was used to prevent pneumocystis infection. Antibacterial prophylaxis or colony-stimulating factors were not given. Patients were managed according to the same protocol and guidelines (except for the serotherapy) by the same staff throughout the study.
Blood for chimerism analyses was sampled biweekly for at least 3 months and until stable full donor chimerism was achieved, and monthly or less frequently thereafter. Chimerism analysis was performed using PCR for short tandem repeats on sets of polymorphic genes chosen for each individual patient-donor pair, with a sensitivity of 2 per cent 20 on total blood nucleated cells and separated CD2-positive T cells. When appropriate, bone marrow and/ or CD19-positive cells were additionally tested. DLI was given in graded dosages owing to mixed chimerism with or without imminent rejection, and with or without other therapies for relapse/incomplete remission, 7 and repeated if required.
Diseases were risk-assessed as follows: Standard risk: AML CR1, CML first chronic phase. High risk: Refractory malignancy, CML following blastic crisis, myeloma with progression post autologous transplantation. Intermediate risk: others.
Statistics
Daily blood tests were performed from the start of conditioning until discharge. Clinical check-up was performed at our department at least weekly for a minimum of 3 months, and as required thereafter. Lymphocyte subset counts were assessed biweekly for 3 months, and monthly for the subsequent 3 months. Non-parametric statistical analyses were performed using Statistica software, with individual Mann-Whitney U analyses of results from each sampling day (lymphocyte counts achieved from Cell-Dyn 4000 cell counter (Abbott Laboratories) in patients treated during [2001] [2002] [2003] or sampling period (lymphocyte subsets). 
Results
Engraftment and resource requirements
The groups were similar as regards age, diagnoses and risk factors (Table 1) . One patient with CML chronic phase who received bone marrow stem cells from an unrelated donor and Campath for 3 days failed to engraft. He subsequently had mobilized blood stem cells from another unrelated donor with ATG, with good engraftment but grade IV GvH. All others had good primary engraftment (Table 2) . Patients receiving Campath for 3 days had significantly fewer days with fever, and required less antibiotics and transfusions than did ATG-treated patients.
Immune recovery and chimerism There was no difference between the groups as regards recovery of neutrophil and platelet counts. However, blood lymphocyte counts were significantly lower each day from day þ 4 to day þ 21 in patients who received Campath for 3 days as compared to those who had ATG or Campath for 1 day (Figure 1 ). Patients treated with Campath for 3 days also subsequently had significantly lower lymphocyte subset counts than patients treated with ATG or Campath for 1 day (Figure 2a-d ).
More ATG-treated patients had consistent full donor chimerism than patients receiving Campath for 3 days, with intermediate outcome for Campath 1 day (Table 3) . In eight patients mixed chimerism and lymphocytosis were seen simultaneously, with transient recipient-derived T-cell counts of 500/ml up to 2000/ml. However, all patients with mixed chimerism successfully reverted to full donor chimerism through withdrawal of immune suppression and/or donor lymphocyte infusions.
Graft-versus-host disease
The primary graft-versus-host disease incidence was low (Table 4) . However, owing to the frequent requirements for donor lymphocyte infusions to revert mixed chimerism with or without imminent rejection among patients given Campath, and the high incidence of GvH following DLI despite graded dosing, 21 the overall incidence of GvH rose. GvH usually developed while the proportion of recipientderived T cells was dropping, but well before full donor chimerism was achieved, as previously shown. 22 
Table 2
Hematologic recovery and resource requirements according to study group (median and quartile values) Figure 1 Median values for daily lymphocyte counts ( Â 10 9 /l, log scale) from the start of conditioning at day À5 until day 21 for 11 patients receiving Thymoglobulin, 20 patients receiving Campath for 3 days, and 12 patients receiving Campath for 1 day. CLL patients excluded from analysis. The Campath 3-day group had lower lymphocyte counts than the ATG group (Po0.05 on all days þ 4 to þ 21), and also lower compared to the Campath 1 day group (Po0.05 on all days þ 7 to þ 21 (Mann-Whitney U test on data from individual days).
Infections
There was a limited requirement for intravenous antibiotics during the peritransplant period (Table 2 ). Among CMVpositive patients, 15/17 and 15/21 required ganciclovir for CMV reactivation in the ATG and Campath 3 day groups, respectively. 23 CMV-retinitis was seen in two patients in the Campath 3-day group but not among the others (Table 5) . Adenovirus was identified in one patient in each of the three groups, but recovery was only seen in the Campath 1-day group. EBV-induced lymphoproliferative disease was seen in one patient with CML chronic phase and unrelated blood stem cells given Campath for 3 days, and another had febrile EBV reactivation. Both responded well to rituximab and low-dose donor lymphocytes. Fungal infections and fatal bacterial infections were more frequent in patients who had Campath for 3 days than in those receiving ATG or Campath for 1 day.
Causes of death
The total tumor-related mortality was 21%, and low in all groups (Table 6 ). However, the non-relapse mortality was greater in the Campath 3-day-treated group, mostly owing to the increased number of fatal infections. Other causes of non-relapse mortality are also listed in Table 5 . 6 /l, log scale) in 10 time intervals following allogeneic transplantation for 27 patients receiving Thymoglobulin, 14 patients receiving Campath for 3 days, and 12 patients receiving Campath for 1 day during adjusted conditioning. CLL patients were excluded from CD19 cell analysis. Vertical bars by the y-axis indicate normal ranges. Patients who had received Campath 3 days had continuously lower CD4 cell counts from week 9 to 18 than patients with Campath for 1 day, lower CD8 cell counts on weeks 5-26, and lower CD19 cell counts on weeks 5-18 (Mann-Whitney U test on data from individual sampling periods, Po0.05, several comparisons yielded Pvalueso0.01).
Table 3
Overall chimerism status according to study group (number of patients and percentages).
Chimerism status ATG (n ¼ 29) Campath 3 days (n ¼ 26) Campath 1 day (n ¼ 14)
Full donor chimerism at all samplings 17 (59%) 6 (23%) 6 (43%) Minor (o10% recipient) mixed chimerism 6 (21%) 2 (8%) 1 (7%) Major (410% recipient) mixed chimerism 6 (21%) 18 (69%) 5 (36%) Posttransplant recipient-derived T cell count 4100/ml 1 (3%) 9 (35%) 5 (36%)
Indicates presence of recipient-derived blood cells at any sampling from day 28 and later. w 2 -analysis: ATG vs Campath 3 days, Po0.01; Campath 3 days vs 1 day, P ¼ 0.1. Overall survival Fourteen patients have died from malignancy, and 16 from non-malignant causes. Within 100 days, one ATG-and one Campath 3-day-treated patient died from adenovirus and Aspergillus, respectively (o4%). Overall survival was excellent in the ATG-treated group, but impaired in the Campath 3-day-treated patients ( Figure 3 , P ¼ 0.006). This tendency was similar in the subgroups of patients transplanted with grafts from related as well as unrelated donors, and especially clear among standard/intermediate risk patients, of whom 10/17 Campath 3-day-treated patients died as compared to 2/18 ATG-treated patients (Overall survival, Log-rank test, P ¼ 0.0014). The group receiving Campath for 1 day had the same overall survival as the ATG group, although in the subset of standard-and intermediate risk, ATG patients did better (P ¼ 0.025).
Discussion
Serotherapy is commonly used as part of non-myeloablative conditioning for allogeneic transplantation to avoid rejection and prevent GvH. Many protocols have been used, and some comparisons made in non-randomized studies. [24] [25] [26] [27] [28] However, the impact of different protocols on lymphoid depletion and recovery has not been properly evaluated, 29 although some differences in lymphocyte recovery have been noted. 25, 26 We prospectively evaluated three different serotherapy schedules with a single prospective protocol on adjusted conditioning of 69 patients with a median age of 54 years, and mainly with high-risk hematological malignancies, in a single institution. Conditioning aimed to provide sustained antitumor activity with limited toxicity, and early establishment of a full donor chimerism for rapid achievement of the graft-versusmalignancy effect. All patients came from the same limited catchment area. We included all eligible patients during a limited time period, and the prospective patient groups were very similar as regards age, diagnoses and risk factors (Table 1) , and they were all managed with the same guidelines by the same team. We now present outcome with a median follow-up of 55, 41 and 30 months, respectively, in the three treatment cohorts.
ATG has significant acute side effects. 10 By replacing i.v. ATG with subcutaneous Campath, we hoped for less early toxicity, a synergistic antitumor effect in lymphoid malignancies, and a reduced risk of EBV-induced lymphoproliferative disease.
14 Campath is registered for intravenous administration, which leads to significant acute side effects. In order to simplify dosing and reduce toxicity we used the subcutaneous route. The short-term results with Campath for 3 days in our second cohort were very beneficial with no acute side effects, neither general nor local 30 , and a reduced need for transfusions and antibiotics (Table 2) , probably related to less inflammatory reaction during conditioning. An association between ATG dose and transfusion requirement following non-myeloablative transplant has been previously reported. 31 Engraftment in our study was uneventful, except for one patient with CML chronic phase who rejected an unrelated marrow harvest. a Primary rejection of unrelated marrow graft with Campath, good take from mobilized blood stem cell from another unrelated donor graft with ATG, grade IV GvH. Table 6 Current transplant-related mortality and tumor-related mortality according to study group and risk category (number/total number; percentage) We identified stronger lymphocyte depletion and slower recovery of lymphoid subsets following 3 days of Campath instead of ATG (Figures 1 and 2) , and this eventually resulted in more mixed chimerism (Table 3) , with a greater need for donor lymphocyte infusions, and more importantly, more opportunistic and fatal infections (Table 5) . In contrast to what we had expected, 14 we also had more problems with EBV-reactivation following Campath. Depletion of circulating B cells was thus not sufficient for eradicating EBV, and the delayed T cell recovery following Campath enabled reactivation of persisting EBV. Adenovirus was seen in both ATG and Campath-treated patients, 32, 33 and CMV reactivation was common in all groups, as previously reported for patients undergoing allotransplantation with reduced-intensity conditioning. 12, 23 CMV retinitis, however, was only seen in patients receiving Campath for 3 days, and we had more problems with fungal disease as well as more fatal bacterial infections and pneumonias; these occurred in patients who had recently recovered from GvH-related problems. Donor lymphocyte infusions were required, and, in contrast to what is reported from mouse studies, 34 GvH frequently developed during reconversion to full donor chimerism, which necessitated reinstitution of immune suppression, which in turn resulted in more severe and opportunistic infections. Whether this enhanced immune deficiency was due to the greater effect of Campath than of ATG on T cells, or due to Campath effects on B cells or on other cell types, such as antigenpresenting cells, is unclear.
In our study, the enhanced immune suppression resulted in an impaired overall survival. This is in contrast to the UK single-arm multi-center study reports on 44 and 78 patients, respectively, 11, 24 where overall survival was encouraging, despite problems with viral infections. 12, 32, 33 However, these patients were considerably younger (median ages 41 and 44 years, as compared to 54 years in our study), and the median follow-up was only 9 and 13 months, respectively. 11, 24 There were also other differences between the protocols. The overall dose of Campath was similar; 90 mg in our 3-day study group (30 mg i.v. days À3 to À1), and 100 mg in the UK study (20 mg i.v. days À8 to À4), but our antibody administration was closer to the graft infusion, which might have resulted in greater in vivo T-cell depletion of the graft. Another possibility is that the subcutaneous route provides sustained exposure of the antibody to immune cells, enhancing the immunosuppressive action. Our chemotherapy was slightly different, although this is not likely to have had an influence on subsequent immune recovery. However, our post transplant immunosuppression always contained MMF for the first 4 weeks in addition to cyclosporin A, whereas most UK patients had cyclosporin alone and some had additional methotrexate. It seems likely that the combination of Campath and MMF, although very well tolerated by the patients, induced the very strong and durable immunosuppression.
We thus revised the Campath protocol from daily injections for 3 days just before transplant to one vial only on day À5. This latter schedule of Campath for 1 day is shown here to give the same lymphocyte depletion and recovery as ATG, and the same overall survival, with less toxicity.
Subcutaneous Campath provides a very simple and nontoxic mode for enhanced immunosuppression, which resulted in a very low early complication rate. However, as immune reconstitution was significantly delayed with the three-day schedule, more problems with mixed chimerism and infections developed. Our alteration with reduced dose and increased time from Campath-injection to graft infusion results in effective immune suppression of the host, minimal immediate side effects, a balanced in vivo T-cell depletion of the graft, and a positive long-term outcome. Daily blood lymphocyte counts during the first weeks is a simple way to monitor and predict the level of immune status.
